• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Ovid, Angelini Pharma Announce Agreement for OV101 americanpharmaceuticalreview
    July 22, 2020
    Ovid Therapeutics and Angelini Pharma announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union, other countries..
  • Ovid, Angelini Pharma Enter Exclusive License Agreement contractpharma
    July 14, 2020
    To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in Europe.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service